trial

Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic Episode

NCTId NCT05384392
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 217 (estimated)
Sponsored by University Hospital, Brest
Primary completion 2027-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
217 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2025-03-27
Primary completion
2027-03
Eligibility
ALL · 15 Years · 30 Years

Interventions & indications

Drugs
Recorded interviewClinical scalesBlood sample

Sponsors

University Hospital, BrestLead Sponsor

Sites

5 total
Angers, FranceBrest, FranceNantes, FranceRennes, FranceTours, France

Facts & assertions

4 sourced
Enrollment
217
Phase
NA
Primary Completion Date
2027-03
Status
RECRUITING
relationships
The graph out of here
drug
Recorded interview
drug
Clinical scales
drug
Blood sample
drug
lead_sponsor
University Hospital, Brest
company
indication
Bipolar Disorder
indication
First-Episode Psychosis
indication
Schizophrenia
indication